
India approves 30% margin cap for cancer drugs
The proposal could cut prices and save patients ₹2,500 crore annually
Overview
Cancer patients in India could pay less for many medicines if the government caps drug-store and distributor markups at 30%. The plan targets , where large markups can sharply raise prices above what manufacturers charge. It follows a 2019 measure covering 42 medicines. The government says that policy cut prices for 526 brands by up to 90% and saved patients about ₹984 crore a year.
The new plan could cover more than 100 branded and generic drugs, including imported and patented medicines. Officials estimate price cuts of 20% to 70% and yearly savings of about ₹2,500 crore. Patients will see no benefit until an expert committee chooses the drugs and the sets their prices. Lower markups could also worry pharmacies and manufacturers if supplies are threatened, leaving drug supply and industry compliance uncertain.
Timeline
Government projects larger price reductions
Officials estimated that affected s could decline by about 20% to 70%, depending on existing . The government projected annual patient savings of approximately . The estimate will depend on which medicines enter the positive list and the margins currently embedded in their prices.
Proposal covers broad medicine categories
The proposed exercise is intended to cover identified non-scheduled medicines across branded and generic products. Its reported scope also includes domestic and imported medicines, as well as patented and . More than 100 medicines, including several , were expected to be considered.
DGHS committee prepares the positive list
An under the was tasked with recommending the of anti-cancer medicines. Reports said the committee was expected to submit its recommendations by October 14. The final list, rather than the headline cap alone, will determine the policy’s coverage.
NPPA approves a wider cap in principle
The approved in principle a 30% for identified non-scheduled anti-cancer medicines under . The decision was conditional on finalising the medicines covered. Scheduled medicines, which already have regulated , are distinct from the non-scheduled products targeted by this proposal.
Implementation challenges arise for cancer-drug margin cap
The cap affects manufacturers, importers, wholesalers, and retailers, while implementation requires restickering affected products and managing . The government also emphasized maintaining availability as the policy lowers patient prices.
NPPA must notify prices after the list is final
The proposal was not yet a final because the covered list still required expert recommendations. After the list is finalised, the NPPA is expected to notify revised prices and oversee implementation. Practical issues include compliance, existing wholesaler and retailer inventory, and the timing of revised MRPs.
High margins remain a concern for non-scheduled drugs
The government’s renewed policy focus reflects continuing concern over medicines outside the scheduled list, where do not directly regulate trade margins. Reports cited official estimates that on some non-scheduled cancer medicines average about 170%. This left room for large differences between stockist prices and patient-facing MRPs.
Government records the pilot’s patient savings
A parliamentary record reiterated that the 2019 trade-margin order covered 42 . It said s for 526 brands fell by up to 90%. The record put estimated annual patient savings at approximately ₹984 crore.
2019 intervention cuts prices across 526 brands
The government reported that the 2019 pilot reduced prices for , with some reductions reaching about 90%. Average reductions were reported at roughly 50% in later government and media accounts. Estimated annual savings for cancer patients were about ₹984 crore.
NPPA caps margins for 42 cancer drugs
The invoked its public-interest powers under . It capped at 30% for 42 selected non-scheduled anti-cancer medicines. The measure targeted the gap between manufacturer prices and retail prices.